the parts that I (particularly) like.......
Our primary focus is on using transgenic technology to produce monoclonal antibodies.
(snip)
GTC is actively participating in the field of monoclonal antibodies through
a number of collaborations. The Company is developing a transgenic version of
Remicade-Registered Trademark- in a collaboration with Centocor. Also, GTC is
developing transgenic versions of eight additional monoclonal antibodies/Ig
fusion molecules, the cell culture versions of which are currently in clinical
trials, including D2E7 and MAK195 for BASF, CTLA4Ig and an Ig fusion molecule
for Bristol-Myers Squibb, Antegren for Elan, BR96 for Seattle Genetics, PRO542
for Progenics and a therapeutic recombinant protein for Alexion.
(snip)
The ATIII LLC has initiated a collaboration with Genzyme Molecular Oncology,
a division of Genzyme, to jointly develop a form of transgenic ATIII for
potential application as an angiogenesis inhibitor in the field of oncology.
(snip)
Millennium Pharmaceuticals
|
